Your browser doesn't support javascript.
loading
ACKR1 Alleles at 5.6 kb in a Well-Characterized Renewable US Food and Drug Administration (FDA) Reference Panel for Standardization of Blood Group Genotyping.
Srivastava, Kshitij; Khil, Pavel P; Sippert, Emilia; Volkova, Evgeniya; Dekker, John P; Rios, Maria; Flegel, Willy A.
Affiliation
  • Srivastava K; Department of Transfusion Medicine, NIH Clinical Center, NIH, Bethesda, Maryland.
  • Khil PP; Laboratory Medicine, NIH Clinical Center, NIH, Bethesda, Maryland.
  • Sippert E; Office of Blood Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
  • Volkova E; Office of Blood Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
  • Dekker JP; Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland.
  • Rios M; Office of Blood Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
  • Flegel WA; Department of Transfusion Medicine, NIH Clinical Center, NIH, Bethesda, Maryland. Electronic address: waf@nih.gov.
J Mol Diagn ; 22(10): 1272-1279, 2020 10.
Article in En | MEDLINE | ID: mdl-32688055
The glycoprotein encoded by the ACKR1 gene expresses the Duffy blood group antigens and is a receptor for malaria parasites. We recently described 18 long-range ACKR1 alleles in an autochthonous population of a malaria endemic region. Extending this work, we sequenced the gene in a 53-sample repository established by the US Food and Drug Administration (FDA) as reference reagents for blood group genotyping. The FDA samples have been characterized for 19 genes; however, long-range haplotype information for these genes, including ACKR1, was lacking. We used a hybrid approach, novel for this type of gene, to characterize ACKR1 by combining two next-generation sequencing technologies, the short-read massively parallel sequencing and the long-read nanopore sequencing. The expedient integration of data from both next-generation sequencing systems were necessary and sufficient to allow determination of all 25 long-range ACKR1 alleles found in the 53 samples accurately. All 25 alleles identified in our current FDA cohort were novel and, unexpectedly, none had been observed among the 18 alleles in our previous study. The alleles will be useful for validation, calibration, and proficiency testing of red cell genotyping. The lack of any overlap between the ACKR1 alleles in the two studies documents differences in mutation rate and recombination frequency among populations. The exact haplotype and their interethnic or interpopulation dissimilarities can influence disease susceptibility and therapy.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: United States Food and Drug Administration / Blood Group Antigens / Receptors, Cell Surface / Base Pairing / Duffy Blood-Group System / Alleles / Genotyping Techniques Type of study: Prognostic_studies Limits: Humans Country/Region as subject: Africa / America do norte Language: En Journal: J Mol Diagn Journal subject: BIOLOGIA MOLECULAR Year: 2020 Document type: Article Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: United States Food and Drug Administration / Blood Group Antigens / Receptors, Cell Surface / Base Pairing / Duffy Blood-Group System / Alleles / Genotyping Techniques Type of study: Prognostic_studies Limits: Humans Country/Region as subject: Africa / America do norte Language: En Journal: J Mol Diagn Journal subject: BIOLOGIA MOLECULAR Year: 2020 Document type: Article Country of publication: United States